Merck Expands Kidney Cancer Portfolio with KEYTRUDA and WELIREG

The news indicates that Merck is expanding its kidney cancer portfolio, which is positive in the long term but does not provide a concrete catalyst to impact the price in the short term. Technical indicators present a weak outlook: the RSI is neutral at 42, the MACD is below zero, and the stock is trading below both the SMA20 and SMA50. The last close was at 113.88, down 1.36%, confirming short-term pressure. Although the news is positive, the weakness in the technical structure and the bearish trend make it difficult to determine a clear direction.